

Nicola FUSCO, M.D.

Gender: **Male**
Country: **Italy**
Date of Birth: **23-Aug-1981**

Permanent Address:
Milan (MI), Italy

Mobile: **+39-338-5472641**
Office 1: **+39(02)9437.2079**

E-mail for correspondence:
nicola.fusco@unimi.it
nicola.fusco@ieo.it

Keywords: Breast Pathology,
Predictive pathology, Digital pathology,
Molecular Pathology, Translational
research.

Current positions

- 01/12/2022 – present:** Director, Division of Pathology, IRCCS European Institute of Oncology (IEO), Milan, Italy.
- 05/07/2021 – present:** Director, Biobank for Translational and Digital Medicine Unit, IRCCS European Institute of Oncology (IEO), Milan, Italy.
- 01/03/2020 – present:** Associate Professor (Pathology, SSD MED/08), University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy
- 06/01/2020 – present:** Appointed Pathologist, Division of Pathology, IRCCS European Institute of Oncology (IEO), Milan, Italy.
- 09/2018 – present:** Appointed Professor, Ph.D. Program in Translational Medicine, University of Milan, Italy.
- 11/2017 – present:** Appointed Professor, Residency Program in Pathology, University of Milan, Italy.
- 11/2017 – present:** Appointed Professor, Medical School and International Medical School, University of Milan, Italy.

Education, certifications, and academic titles

- 03/10/2022:** National Scientific Qualification as Full Professor in Pathology (Abilitazione Scientifica Nazionale a Professore di Prima Fascia) SSD MED/08, SD 06/A4 (Italian Ministry of Education, Universities, and Research)
- 01/2022:** Targos Molecular Pathology certification “Trainer for PD-L1 Testing (22C3) in TNBC”, Kassel, Germany.
- 19/04/2019:** National Scientific Qualification as Associate Professor in Pathology (Abilitazione Scientifica Nazionale a Professore di Seconda Fascia) SSD MED/08, SD 06/A4 (Italian Ministry of Education, Universities, and Research)
- 01/2019:** Targos Molecular Pathology certification “Trainer for PD-L1 Testing (22C3) in Head & Neck Carcinoma”, Kassel, Germany.
- 18/05/2015:** School of Pathology, University of Milan, Italy.
- 31/10/2008:** Doctor of Medicine (Bachelor of Medicine, Bachelor of Surgery), University of Eastern Piedmont, Novara, Italy; Ordine dei Medici Chirurghi e degli Odontoiatri di Milano - Board position: OMCeO-MI 47749

Past positions

- 01/12/2016 – 30/11/2019:** Attending Pathologist, Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- 01/12/2016 – 30/11/2019:** Pathology Research Associate (RTD-A, SSD MED/08), University of Milan, Department of Biomedical, Surgical and Dental Sciences, Milan, Italy.
- 1/2016 – 12/2016:** Post-Doc Fellow, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy.
- 6/2015 – 12/2016:** Research Fellow, Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- 5/2010 – 5/2015:** Resident in Pathology / Pathology Fellow, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, IRCSS Istituto Clinico Humanitas, Rozzano (MI), Italy, Luigi Sacco Hospital, Milan, Italy, and San Paolo Hospital, Milan, Italy.
- 11/2013 - 10/2014:** Visiting Investigator, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- 7/2009 - 5/2010:** Research Fellow, San Paolo Hospital, Milan, Italy.

6/2008 - 6/2009: Post-graduate training in Pathology (Tenure), Novara University Hospital, Novara, Italy. Awards and achievements

- 05/2023 – present:** Member of the “Quality and Safety” Working Group within the Italian Society of Pathology (SIAPeC).
- 05/2023 - present:** Member of the “System Digitization Working Group” within the “Future Lombardy Healthcare Forum”.
- 05/2023 - present:** Member of the “Research & Development” Working Group within the “Future Lombardy Healthcare Forum”.
- 03/2023 - present:** Member of the Board of Directors, Biobanking and BioMolecular Resources Research Infrastructure of Italy (BBMRI)
- 01/2023 - present:** Chair of the “Quality Control & Accreditations Committee”, International Society of Liquid Biopsy (ISLB)
- 12/2021 - present:** Member of the “Gruppo di approfondimento tecnico sulle biobanche (G.A.T. Biobanche) - Technical Study Group on biobanks (G.A.T. Biobanks), Regione Lombardia – Direzione generale welfare.
- 2022:** First Author of the “Recommendations for the management of bioptic and surgical samples of patients with breast carcinoma candidates for neo adjuvant therapy” from the Study Group of Breast Pathology / Italian Society of Pathology (GIPaM/SIAPeC)
- 06/2020 – present:** Co-founder and Scientific Board member at 4oncommunity.com a ticketing service and portal for oncology and molecular pathology specialists where to share experience and exchange information with the oncology and predictive pathology community.

12/2019: Young Survival Coalition (YSC) mention “Guiding Researchers & Advocates to Scientific Partnership” for the work “Integrated analysis of mismatch repair, PD-L1, and immune microenvironment status in pregnancy-associated breast cancers” – San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA, December 2019

09/2015: Best Young Speaker Award – Italian Society of Pathology (SIAPeC) Annual Meeting, Milan, Italy.

Language Skills: Italian (mother tongue), English (full proficiency)

Funded projects

- European Research Council (ERC) Synergy 2022. Progetto: “SHAPINCELLFATE: Impact of cell shapes on cell behaviour and fate” Co-pi with IEO, partner organization University of Milan (2022-2025) 231.276 €
- Bando per borse aggiuntive di dottorato su tematiche dell'innovazione e green D.M. n. 1061 del 10 agosto 2021 – a.a. 2021/2022, progetto Digital Biobank for Translational Medicine (D-B4MED) @ IEO, partner industriale: Life Reply, Business Unit di Santer Reply spa. Finanziata 1 borsa nell'ambito della Scuola di Dottorato in Medicina Traslazionale, Università degli Studi di Milano (proponente Prof. Fusco).
- Bando Ricerca Finalizzata GR-2019-12368592 - Combined genomic and proteomic characterization of follicular thyroid lesions: a project to "save thyroid" (2021-2024) 149.600 €
- IFALT - Insufficienza Respiratoria in Riceventi Trapianto di Polmone (ARS01_00530) PON PNR 2015-2020 Ente finanziatore: MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA Role: Collaborator Finanziamento complessivo: 4.746.999€

Scientific organizations and Foundations

- Italian Society of Pathology (SIAPeC) - Member
- Italian Group for the Study of Breast Pathology (GIPaM/SIAPEC) – Member of the Council
- European Society of Pathology - Member
- International Society of Liquid Biopsy (ISLB) – Member and Chair of the “Quality Control & Accreditations Committee”
- OXIAMO Onlus – Member of the Scientific Committee (12/2018 – present)

Teaching activity (SSD MED/08)

#docente responsabile del modulo

UNIVERSITA' DEGLI STUDI DI MILANO

2017-Present MEDICINA E CHIRURGIA - International Medical School - (Classe LM-41)

- SYSTEM DISEASES 3 (D56-107), MODULO PATHOLOGY
- SYSTEM DISEASES 2 (D56-106), MODULO PATHOLOGY
- SYSTEM DISEASES 1 (D56-105), MODULO PATHOLOGY
- NEUROBIOLOGY, HUMAN BEHAVIOUR AND CLINICAL NEUROSCIENCE (D56-114), MODULO PATHOLOGY#
- CLINICAL ONCOLOGY AND RADIOTHERAPY (D56-111), MODULO PATHOLOGY#
- CLINICAL AND SURGICAL PATHOLOGY (D56-115), MODULO UNICO

2016-2020 MEDICINA E CHIRURGIA - Polo Centrale (Classe LM-41)

- DIDATTICA NON FORMALE (D51-31)
- SEMEIOLOGIA E PATOLOGIA DEGLI APPARATI I (D51-65), MODULO ANATOMIA PATOLOGICA#
- Coordinator of the internship “*Clinical and Experimental Pathology*”
- Coordinator of the Internship “*Clinical Management of Breast Cancer*”

2019-Present MASTER: FARMACIA E FARMACOLOGIA ONCOLOGICA - II LIVELLO (95M-28.20.1 - Edizione unica)

- ANATOMIA PATOLOGICA IN ONCOLOGIA (95M-28)

2020-2021 MASTER: PREVENZIONE, GENETICA E TRATTAMENTO DEL TUMORE MAMMARIO EREDITARIO – II LIVELLO (MA1-3.21.1 - Edizione unica)

- GENI AD ALTA PENETRANZA PER IL CARCINOMA MAMMARIO
- ANATOMIA E ISTOLOGIA PATOLOGICA

2021-Present MASTER: PSICONCOLOGIA - II LIVELLO (MA2-9.23.1 - Edizione unica)

- EZIOPATOGENESI DEL TUMORE, PERCORSI DI CURA E INTEGRAZIONE DELLA PSICONCOLOGIA (MA2-9)

2021-2022 MASTER: ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN CANCER MEDICINE - II livello (MA8-11.22.1 – Edizione Unica)

- ANALISI DEI CASI DI STUDIO NEL MOLECULAR TUMOR BOARD (MA8-11)

2019-Present Ph.D. PROGRAM IN TRANSLATIONAL MEDICINE

- Appointed Professor with several lines of research:
- BIOMARKERS IN PRECISION MEDICINE: BRIDGE THE GAP BETWEEN TRANSLATIONAL RESEARCH AND CLINICAL PRACTICE (R46-45)#
- THE IMPACT OF TRANSLATIONAL RESEARCH IN THE CLINICAL MANAGEMENT OF CANCER PATIENTS (R46-34)#

- IMMUNOPATHOLOGY IN TRANSLATIONAL RESEARCH AND CLINICAL PRACTICE (R46-27)#
- MOLECULAR AND IMMUNOPATHOLOGY (R46-9)#

2021-Present BIOMEDICAL OMICS (Classe LM-9)

- OMICS IN DIAGNOSTICS

2015-Present SCUOLA DI SPECIALIZZAZIONE IN ANATOMIA PATOLOGICA

- JOURNAL CLUB DI ANATOMIA PATOLOGICA IN LINGUA INGLESE (PRIMO ANNO) (56S-17), MODULO UNICO#
- JOURNAL CLUB DI ANATOMIA PATOLOGICA IN LINGUA INGLESE (SECONDO ANNO) (56S-12), MODULO UNICO#
- JOURNAL CLUB DI ANATOMIA PATOLOGICA IN LINGUA INGLESE (TERZO ANNO) (56S-6), MODULO UNICO#
- JOURNAL CLUB DI ANATOMIA PATOLOGICA IN LINGUA INGLESE (QUARTO ANNO) (56S-2), MODULO UNICO#
- ANATOMIA PATOLOGICA 1 (56S-19), MODULO LEZIONI PRATICHE#
- INGLESE 2 (02S-15), MODULO UNICO#

2019-2020 CORSO DI PERFEZIONAMENTO: METODOLOGIA ED ETICA DELLA SPERIMENTAZIONE CLINICA ONCOLOGICA (MZ8)

- ANATOMIA PATOLOGICA IN ONCOLOGIA (MZ8-1)

2017-2020 ODONTOIATRIA E PROTESI DENTARIA (Classe LM-46) – School of Dentistry, University of Milan, Italy

- ANATOMIA PATOLOGICA (D54-23), MODULO UNICO

2017-2018 School of Dental Hygienist, University of Milan, Italy (11/2017 – 09/2018)

- SCIENZE MEDICO-CHIRURGICHE (D79-14), MODULO ANATOMIA PATOLOGICA (DOCENTE RESPONSABILE DEL MODULO)

Other academic activities

- **Ph.D. Program in Clinical and Translational Sciences, University of Pisa, Italy**
 - Discussant for the thesis: “The metastatic potential of grade 1 breast carcinoma of no special type: a deep insight into putative molecular mechanisms” by Claudia Scopelliti, December 2019
- **Ph.D. Program in Translational and Molecular Medicine, University of Milano-Bicocca, Italy**
 - Discussant for the thesis: “MALDI-MSI in the study of glomerulonephritis: Possible molecular indicators of CKD progression” by Andrew Smith, March 2017
- **Corso di Master “Metodologie di anatomia patologica per lo studio dei marcatori predittivi di risposta terapeutica”, University of Naples Federico II.**
 - Lecture: “Biomarcatori nel carcinoma mammario e ovarico”. 10 July 2020. Virtual Meeting.
- **Corso di aggiornamento professionale universitario in riabilitazione oncologica, University of Eastern Piedmont**
 - Lecture: “Biomarcatori, predittività e complicità di interesse riabilitativo nel carcinoma della mammella”. December 2020. Blended Virtual Course.

Thesis supervisor2022

- “Breast cancer during pregnancy as a special type of early-onset breast cancer: insights into the tumor microenvironment and immune transcriptome” by Konstantinos Venetis, Ph.D. Program in Translational Medicine, University of Milan (**Relatore**)
- “Artificial intelligence and machine learning in computational pathology through self-supervised learning and visual transformers” by Carmelo Lupo, Master Universitario di II livello in Artificial Intelligence and Machine Learning in Cancer Medicine, University of Milan (**Relatore**)
- “Creation of a Digital Biobank in a referral Cancer Center” by Giuseppina Bonizzi, Master Universitario di II livello in Artificial Intelligence and Machine Learning in Cancer Medicine, University of Milan (**Relatore**)

2021

- “The molecular landscape of mucoepidermoid carcinoma of the breast” by Silvia Andoloro, Medical and Pharmaceutical Biotechnology, University of Pavia (**Correlatore**)
- “Morpho-molecular characterization of tumor immune microenvironment in ductal carcinoma in situ of the breast for the identification of women at higher risk of recurrence” by Alberto Concardi, School of Medicine, University of Milan (**Relatore**)
- “Association of tissue and circulating biomarkers with radiomic features in patients with advanced non-small cell lung cancer” by Stefano Natangelo, School of Medicine, University of Milan (**Relatore**)

2020

- “Analisi dell'espressione di microRNA nelle diverse popolazioni cellulari dei carcinomi della mammella di tipo osteoclast-like” by Alice Premoli, Laboratory Technician Bachelor's Degree, University of Milan (**Relatore**)

2019

- “Capturing the role of the immune regulatory system in pregnancy-associated breast cancers” by Roberto Croci, School of Medicine, University of Milan (**Correlatore**)

2018

- “Assessing the risk of breast cancer related lymphedema: a multidisciplinary approach for a paradigm-shift in the clinical management” by Anna Michelotti, School of Medicine, University of Milan (**Relatore**)
- “Caratteristiche istologiche della biopsia osteomidollare nei pazienti con sindromi mielodisplastiche in trattamento con azacitidina” by Livia Maria Rita Marcon, School of Medicine, University of Milan (**Correlatore**)
- “Caratteristiche istologiche della biopsia osteomidollare nei pazienti con sindromi mielodisplastiche in trattamento con eritropoietina” by Marco Barella, School of Medicine, University of Milan (**Correlatore**)

- “BRAF^{V600E} e ameloblastoma: risultati di uno studio retrospettivo osservazionale multicentrico” by Monica Slongo, School of Medicine, University of Milan (**Correlatore**)
- “Molecular testing for mismatch repair and PTEN status in breast cancer: clinical implications and perspectives in immunotherapy” by Chiara Corti, School of Medicine, University of Milan (**Correlatore**)

2017

- “La realtà aumentata nei tumori del cavo orale: integrare la tecnologia “Narrow Band Imaging” con la patologia molecolare. Uno studio pilota per una chirurgia radicale ultra-personalizzata” by Camilla Mazzucato, School of Medicine, University of Milan (**Correlatore**)
- “PTEN immunohistochemistry is a predictor of mismatch repair status in breast cancer” by Gianluca Lopez, School of Medicine, University of Milan (**Correlatore**)

Editorial activity

Editor:

2023-present: Journal of Liquid Biopsy

2021-2023: Biomedicines (I.F. 4.757), International Journal of Molecular Sciences (I.F. 6.208), Journal of Clinical Medicine (I.F. 4.964), Diagnostics (I.F. 3.992), Journal of Molecular Pathology, Editor of the Topic “Diagnostic Imaging and Pathology in Cancer Research”.

2022-2023: Frontiers in Network Physiology, Editor of the Special Issue “Cancer Biophysics, Survivorship, and Quality of Life”

2022: Cells (I.F. 7.666), Editor of the Special Issue “Predictive Molecular Pathology in Breast Cancer”

2022-present: Oncologie (I.F. 0.900), Editorial Board Member

2021-2022: Journal of Personalized Medicine (I.F. 3.508), Editor of the Special Issue “Advances in Personalized Treatment of Cancer (Powered by: 4oncommunity)”.

2021-2023: BMC Medicine (I.F. 11.150), Editorial Advisor.

2021-2023: Systems Interactions and Organ Networks, Editorial Board Member

2019-2023: Frontiers in Oncology (I.F. 5.738), Associate Editor (Breast Cancer section), Guest Associate Editor (Women’s Cancer section).

2018-2023: Cancer Cell International (I.F. 6.436), Associate Editor

2018-2023: BMC Cancer (I.F. 4.638), Editorial Board Member

2020-2021: Genes (I.F. 4.141), Editor of the Special Issue “Molecular Biomarkers in Solid Tumors”.

Ad-hoc Reviewer for several books, indexed journals, and grant proposals.

Publications

Total number: 167; Total Impact Factor 838.8; Average Impact Factor 5.02; H-index 28 (Scopus) 32 (Scholar)

#corresponding author; *first, co-first, last, co-last

1. **ESR1 mutations in HR+/HER2- metastatic breast cancer: enhancing the accuracy of ctDNA testing**
Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, Mane E, Russo G, Taurelli Salimbeni B, Troncone G, Guerini-Rocco E, Curigliano G, Fusco N*, Malapelle U
Cancer Treat Rev. 2023 Oct [ahead of print] **I.F. 11.8**
2. **Revolutionizing Cancer Research: The Impact of Artificial Intelligence in Digital Biobanking**
Frascarelli C, Bonizzi G, Rosella Musico C, Mane E, Cassi C, Guerini-Rocco E, Farina A, Scarpa A, Lawlor R, Reggiani Bonetti L, Caramaschi S, Eccher A, Marletta S, Fusco N*
J Pers Med. 2023 13(9), 1390 **I.F. 3.5**

CDK4/6 Inhibitors Biomarker Landscape: the most Relevant Biomarkers of Response or Resistance for Further Research and Potential Clinical Utility
Antonarelli G, Taurelli Salimbeni B, Marra A, Esposito A, Locatelli M, Trapani D, Pescia C, Fusco N, Curigliano G, Criscitiello C
Crit Rev Oncol Hematol 2023 Sep [ahead of print] **I.F. 6.2**
3. **Oncological outcomes of Thulium–yttrium–aluminium–garnet (Tm:YAG) laser ablation for penile cancer**
Urology. 2023 Sep [ahead of print] **I.F. 2.1**
4. **Multiparametric MRI-based 5-year risk prediction model for biochemical recurrence of prostate cancer after radical prostatectomy**
Radiology. 2023 Sep [ahead of print] **I.F. 19.7**
5. **Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer**

Ivanova M, Porta FM, d'Ercole M, Pescia C, Sajjadi E, Cursano G, De Camilli E, Pala O, Mazzarol G, Venetis K, Guerini Rocco E, Curigliano G, Viale G, [Fusco N[#]](#)

Virchows Arch. 2023 Sep [ahead of print] **I.F. 3.5**

6. Circulating tumor DNA testing in metastatic breast cancer: Integration with tissue testing

Ranghiero A, Frascarelli C, Cursano G, Pescia C, Ivanova M, Vacirca D, Rappa A, Taormina SV, Barberis M, [Fusco N[#]](#), Guerini Rocco E, Venetis K.

Cytopathology. 2023; 00:1–11. **I.F. 1.3**

7. Contrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the evaluation of breast lobular neoplasia.

Nicosia L, Rotili A, Pesapane F, Bozzini AC, Battaglia O, Pellegrino G, [Fusco N](#), Porta FM, Frassoni S, Bagnardi V, Corso G, Sangalli CA, Cassano E.

Breast Cancer Res Treat. 2023 Aug [ahead of print] **I.F. 3.8**

8. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey

[Fusco N[#]](#), Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G

Crit Rev Oncol Hematol 2023 190:104103 **I.F. 6.2**

9. The tumor immune microenvironment composition and prognostic role in breast cancer during pregnancy changes over gestational ages

Sajjadi E, Venetis K, Ivanova M, Blundo C, Di Loreto E, Scarfone G, Ferrero S, Maggi S, Veronesi P, Galimberti VE, Viale G, Peccatori FA, [Fusco N[#]](#), Guerini-Rocco E

Front Oncol. 2023 July [ahead of print] **I.F. 4.7**

10. Immune biomarkers in triple-negative breast cancer: improving the predictivity of current testing methods.

Porta FM, Sajjadi E, Venetis K, Frascarelli C, Cursano G, Guerini-Rocco E, [Fusco N[#]](#), Ivanova M

J Pers Med. 2023; 13(7):1176 **I.F. 3.4**

11. The immunogram of inflammatory breast cancer

Valenza C, Trapani D, [Fusco N](#), Wang X, Cristofanilli M, Ueno NT, Curigliano G

Cancer Treat Rev 2023; 119(102528) **I.F. 11.8**

12. Trop-2 as an actionable biomarker in breast cancer

Cursano G, Frigo E, Sajjadi E, Ivanova M, Venetis K, Guerini-Rocco E, Criscitiello C, Curigliano G, [Fusco N[#]](#)

Curr Genomics 2023; July [ahead of print] **I.F. 2.6**

13. Technical aspects and validation of custom digital algorithms for hand volumetry.

Nascimben M, Lippi L, [Fusco N](#), de Sire A, Invernizzi M, Rimondini L

Technol Health Care 2023; June [ahead of print] **I.F. 1.6**

14. Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management.

Ivanova M; Porta FM; Giugliano F; Frascarelli C; Sajjadi E; Venetis K; Cursano G; Mazzarol G; Guerini-Rocco E; Curigliano G; Criscitiello C; [Fusco N[#]](#)

Genes 2023 May, 14, 1160 **I.F. 4.141**

15. Value of Artificial Intelligence in Evaluating Lymph Node Metastases.

Caldonazzi N, Rizzo PC, Eccher A, Girolami I, Fanelli GN, Naccarato AG, Bonizzi G, [Fusco N](#), d'Amati G, Scarpa A, Pantanowitz L, Marletta S.

Cancers. 2023; 15(9):2491 **I.F. 6.575**

16. Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies.

Grizzi G, Venetis K, Denaro N, Bonomi M, Celotti A, Pagkali A, Hahne JC, Tomasello G, Petrelli F, Fusco N, Ghidini M.

J Clin Med. 2023; 12(8):2973. **I.F. 4.964**

17. Letter to the Editor regarding the article “Pregnancy-associated breast cancer: a multicenter study comparing clinicopathological factors, diagnosis and treatment outcomes with non-pregnant patients”

Sajjadi E, Venetis K, [Fusco N[#]](#)

Breast Cancer Res Treat. 2023 Mar [ahead of print] **I.F. 4.624**

18. In-house Homologous Recombination Deficiency testing in Ovarian Cancer: a multi-institutional Italian pilot study

Pepe F, Guerini-Rocco E, Fassan M, [Fusco N](#), Vacirca D, Ranghiero A, Venetis K, Rappa A, Taormina SV, Russo G, Rebellato E, Munari G, Moreno-Manuel A, De Angelis C, Zamagni C, Valabrega G, Malapelle U, Troncone G, Barberis M, Iaccharino A.

J Clin Pathol. 2023 Mar [ahead of print] **I.F. 4.467**

- 19. Pathological identification of HER2-Low breast cancer: Tips, tricks, and troubleshooting for the optimal test**
Sajjadi E, Guerini-Rocco E, De Camilli E, Pala O, Mazzarol G, Venetis K, Ivanova M, [Fusco N](#)[#]
Front Mol Biosci. 2023 Mar 10;1176309. I.F. **6.113**
- 20. Computational pathology to improve biomarker testing in breast cancer: how close are we?**
Sajjadi E, Frascarelli C, Venetis K, Bonizzi G, Ivanova M, Vago G, Guerini-Rocco E, [Fusco N](#)[#]
Eur J Cancer Prev. 2023 Mar [ahead of print] I.F. **2.4**
- 21. Immune plasticity in pregnancy-associated breast cancer tumorigenesis.**
Venetis K, Sajjadi E, Peccatori FA, Guerini-Rocco E, [Fusco N](#)[#]
Eur J Cancer Prev. 2023 Mar [ahead of print] I.F. **2.4**
- 22. Targeting post-translational modifications to improve combinatorial therapies in breast cancer: The role of fucosylation**
Antonarelli G, Pieri V, Porta FM, [Fusco N](#), Finocchiaro G, Curigliano G, Criscitiello C
Cells. 2023 Mar 8;12(6):840. I.F. **7.666**
- 23. Characterization of the immune environment in pregnancy-associated breast cancer**
Venetis K, Sajjadi E, Ivanova M, Peccatori FA, [Fusco N](#)[#], Guerini-Rocco E
Future Oncol. 2023 May;19(15):1073-1089. I.F. **3.674**
- 24. Unlocking the resistance to anti-HER2 treatments in breast cancer: The issue of HER2 spatial distribution.**
Giugliano F, Carnevale Schianca A, Corti C, Ivanova M, Bianco N, Dellapasqua S, Criscitiello C, [Fusco N](#), Curigliano G, Munzone E.
Cancers. 2023 Feb, 15, 1385 I.F. **6.575**
- 25. How to manage early metaplastic breast cancer: an all-round multidisciplinary consensus**
Corso G, Criscitiello C, Nicosia L, Pesapane F, Vicini E, Magnoni F, Sibilio A, Zanzottera C, Mannucci S, Marabelli M, Calvello M, Zagami P, Porta FM, Toesca A, Tarantino P, Mazzarol G, La Vecchia C, Bonanni B, Leonardi C, Veronesi P, Fusco N*.
Eur J Cancer Prev. 2023 Jul 1;32(4):348-363. I.F. **2.4**
- 26. First Live-Experience Session with PET/CT Specimen Imager. A pilot analysis in Prostate Cancer and Neuroendocrine Tumor.**
Muraglia L, Mattana F, Travaini LL, Musi G, Bertani E, Renne G, Pisa E, Ferrari EM, Fumagalli Romario U, De Cobelli O, [Fusco N](#), Ceci F.
Biomedicines. 2023 Feb; 11(2), 645. I.F. **4.757**
- 27. Artificial intelligence-based tools applied to pathological diagnosis of microbiological diseases**
Marletta S, L'Imperio V, Eccher A, Antonini P, Santonicco N, Girolami I, Dei Tos AP, Sbaraglia M, Pagni F, Brunelli M, Marino A, Scarpa A, Munari E, [Fusco N](#), Pantanowitz L
Pathol Res Pract. 2023 Feb; 243(154362). I.F. **3.309**
- 28. Malignancies in patients with celiac disease: diagnostic challenges and molecular advances**
Ivanova M, Bottiglieri L, Sajjadi E, Venetis K, [Fusco N](#)
Genes. 2023 Feb; 14(2), 376. I.F. **4.141**
- 29. Spatially Resolved Molecular Approaches for the Characterization of Non-invasive Follicular Tumours with Papillary-like Features (NIFTPs)**
Piga I, L'Imperio V, Principi L, Bellevicine C, [Fusco N](#), Maffini FA, Venetis K, Ivanova M, Seminati D, Casati G, Pagani L, Galimberti S, Capitoli G, Garancini M, Gatti A, Magni F, Pagni F
Int J Mol Sci. 2023 Jan; 24,2567. I.F. **6.208**
- 30. Editorial: Diagnosis and Treatment of Breast Cancer in 2022 -The Rise of Novel Molecular Biomarkers**
[Fusco N](#)[#], Malapelle U, Criscitiello C
Front Mol Biosci. 2023 Jan; 9:1117323 I.F. **6.113**
- 31. Impact of rehabilitation on bone biomarkers in non-metastatic breast cancer women: a systematic review and meta-analysis**
De Sire A, Lippi L, Marotta N, Folli A, Calafiore D, Moalli S, Turco A, Ammendolia A, [Fusco N](#), Invernizzi M
Int J Mol Sci. 2023 Jan;: 24(2), 921 I.F. **6.208**
- 32. The molecular landscape of breast mucoepidermoid carcinoma**
Venetis K, Sajjadi E, Ivanova M, Andaloro S, Pessina S, Zanetti C, Ranghiero A, Citelli G, Rossi C, Lucioni M, Malapelle U, Pagni F, Barberis M, Guerini-Rocco E, Viale G, [Fusco N](#)[#]
Cancer Med. 2023 May;12(9):10725-10737. I.F. **4.711**
- 33. Significant association between FGFR1 mutation frequency and age in central giant cell granuloma**
Niada S, Varazzani A, Giannasi C, [Fusco N](#), Armiraglio E, Di Bernardo A, Cherchi A, Baj A, Corradi D, Tafuni A, Parafioriti A, Ferrero S, Bianchi AE, Gianni AB, Poli T, Latif F, Brini AT
Pathology 2023 Apr;55(3):329-334. I.F. **5.335**

- 34. Clinical features of type 1 and 2 refractory celiac disease: results from a large cohort over a decade**
Barigelletti G, Fabiano S, Rimondi A, Costantino A, [Fusco N](#), Roncoroni L, Cro L, Rossi FG, Alice S, Baldini L, Scaramella L, Croci GA, Pietro S., Gianelli U, Barbieri M, Vaira V, Ferrero S, Tontini G, Vecchi M, Nandi N, Doneda L, Elli L.
Dig Liv Dis. 2023 Feb;55(2):235-242. **I.F. 5.165**
- 35. Diagnostic performance of image-guided vacuum assisted breast biopsy after neoadjuvant therapy for breast cancer: a prospective pilot study of surgical de-escalation**
Rossi EMC, Invento A, Pesapane F, Pagan E, Bagnardi V, [Fusco N](#), Venetis K, Dominelli V, Trentin C, Cassano E, Gilardi L, Mazza M, Lazzeroni M, De Lorenzi F, Caldarella P, De Scalzi A, Girardi A, Sangalli C, Alberti L, Sacchini V, Galimberti V, Veronesi P.
Br J Surg. 2023 Jan 10;110(2):217-224. **I.F. 11.122**
- 36. An indeterminate for malignancy FNA report does not increase the surgical risk of incidental thyroid carcinoma**
Seminati D, Mane E, Ceola S, Casati G, Putignano P, Garancini M, Gatti A, Leni D, Pincelli AI, [Fusco N](#), L'Imperio V, Pagni F
Cancers. 2022 Nov 3;14(21):5427. **I.F. 6.575**
- 37. Analytical performance of next-generation sequencing and RT-PCR on formalin-fixed paraffin-embedded tumor tissues for PIK3CA testing in HR+/HER2- breast cancer**
Venetis K, Pepe F, Munzone E, Sajjadi E, Russo G, Pisapia P, Ivanova M, Bonizzi G, Vacirca D, Rappa A, Ranghiero A, Taormina SV, Viale G, Barberis M, Guerini-Rocco E, Malapelle U, [Fusco N](#)[#]
Cells. 2022 Nov 9;11(22):3545. **I.F. 7.666**
- 38. Ten-year results of hypofractionated whole breast radiotherapy and intraoperative electron boost in premenopausal women**
Leonardi MC, Cormio C, Frassoni S, Dicuonzo S, Fedor C, Intra M, Zarella MA, Morra A, Cattani F, Comi S, [Fusco N](#), Zaffaroni M, Galimberti V, Veronesi P, Dellapasqua S, De Lorenzi F, Ivaldi GB, Bagnardi V, Orecchi R, Rohjas DP, Jereczek-Fossa BA.
Radiother Oncol. 2022 Dec;177:71-80. **I.F. 6.901**
- 39. Efficacy of ultrasound-guided injection combined with personalized rehabilitation in breast cancer women with subacromial pain syndrome: a pilot randomized clinical study**
Lippi L, de Sire A, Folli A, Maconi A, Polverelli M, Vecchio C, [Fusco N](#), Invernizzi M
J Pers Med. 2022 Nov 3;12(11):1833. **I.F. 3.508**
- 40. HER2 in metastatic colorectal cancer: pathology, somatic alterations, and perspectives for novel therapeutic schemes**
Ivanova M, Venetis K, Guerini-Rocco E, Bottiglieri L, Mastropasqua MG, Garrone O, [Fusco N](#)[#], Ghidini M
Life 2022 Sep 9;12(9):1403 **I.F. 3.251**
- 41. Standard operating procedures for biobank in oncology**
Bonizzi G, Zattoni L, Capra M, Cassi C, Taliento G, Ivanova M, Guerini-Rocco E, Fumagalli M, Monturano M, Albin A, Viale G, Orecchia R, [Fusco N](#)[#]
Front Mol Biosci. 2022 Aug 26;9:967310 **I.F. 6.113**
- 42. The evolving landscape of anatomic pathology**
Pisapia P, L'Imperio V, Galuppini F, Sajjadi E, Russo A, Cerbelli B, Fraggetta F, D'Amati G, Troncone G, Fassan M, [Fusco N](#)^{*}, Pagni F, Malapelle U
Crit Rev Oncol Hematol. 2022 Oct;178:103776 **I.F. 6.625**
- 43. Biobanking in the Digital Pathology Era**
Bonizzi G, Zattoni L, [Fusco N](#)[#]
Oncol Res. 2022 Aug 31;29(4):229-233. **I.F. 4.938**
- 44. Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages.**
Sajjadi E, Gaudio G, Terrasi A, Boggio F, Venetis K, Ivanova M, Bertolasi L, Lopez G, Runza L, Premoli A, Lorenzini D, Guerini-Rocco E, Ferrero S, Vaira V, [Fusco N](#)[#]
Front Mol Biosci. 2022 Aug 26;9:894247 **I.F. 6.113**
- 45. Breast cancer during pregnancy as a special type of early-onset breast cancer: analysis of the tumor immune microenvironment and risk profiles**
Sajjadi E, Venetis K, Noale M, Azim HA, Blundo C, Bonizzi G, Di Loreto E, Scarfone G, Ferrero S, Maggi S, Barberis M, Veronesi P, Galimberti V, Viale G, [Fusco N](#)[#], Peccatori FA, Guerini-Rocco E
Cells. 2022 Jul 24;11(15):2286. **I.F. 7.666**
- 46. Integrating Molecular Biomarkers in Breast Cancer Rehabilitation. What Is the Current Evidence? A Systematic Review of Randomized Controlled Trials**
Invernizzi M, Lippi L, Folli A, Turco A, Zattoni L, Maconi AG, de Sire A, [Fusco N](#)^{*}
Front. Mol. Biosci. 2022 Sep 8;9:930361 **I.F. 6.113**
- 47. Axillary web syndrome in breast cancer women: what is the optimal rehabilitation strategy after surgery? A systematic review**
Lippi L, De Sire A, Losco L, Mezzan K, Folli A, Ivanova M, Zattoni L, Moalli S, Ammendolia A, Alfano C, [Fusco N](#), Invernizzi M

- J Clin Med.** 2022 Jul 1;11(13):3839. I.F. 4.964
- 48. Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems**
Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A
J. Pers. Med. 2022 Jun 29;12(7):1073. I.F. 3.508
- 49. Biobank for translational medicine: standard operating procedures for the optimal samples' management**
Bonizzi G, Capra M, Cassi C, Taliento G, Pala O, Sajjadi E, Venetis K, Ivanova M, Monturano M, Renne G, Zattoni L, Guerini-Rocco E, Viale G, Orecchia R, Fusco N#
J Vis Exp. 2022 Nov 30;(189). I.F. 1.424
- 50. Gluten induces subtle histological changes in duodenal mucosa of patients with non-coeliac gluten sensitivity: a multi-center study**
Rostami K, Ensari A, Marsh MN, Srivastava A, Villanacci V, Carroccio A, Aghdaei HA, Bai JC, Bassotti G, Becheanu G, Bell P, Di Bella C, Bozzola AM, Cadei M, Casella G, Catassi C, Ciacci C, Apostol Ciobanu DG, Cross SS, Danciu M, Das PK, Del Sordo R, Drage MG, Elli L, Fasano A, Florena AM, Fusco N, Going JJ, Guandalini S, Hagen KE, Hayman DTS, Ishaq S, Jericho H, Johncilla M, Johnson M, Kaukinen K, Levene A, Liptrot S, Lu L, Makharia GK, Mathews S, Mazzearella G, Nemteanu R, Myint KLV, Mohaghegh-Shalmani H, Moradi A, Mulder CJJ, Ray R, Ricci C, Rostami-Nejad M, Sapone A, Sanders DS, Taavela J, Volta U, Walker M, Derakhshan M
Nutrients 2022 Jun, 14(12), 2487 I.F. 6.706
- 51. FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint**
Cappello F, Angerilli V, Munari G, Ceccon C, Sabbadin M, Pagni F, Fusco N, Malapelle U, Fassan M.
J. Pers. Med. 2022 Jun, 12, 750 I.F. 4.945
- 52. Lights on HBME-1: the elusive biomarker in thyroid cancer pathology**
Cazzaniga G, Seminati D, Smith A, Piga I, Capitoli G, Garancini M, L'Imperio V, Fusco N, Pagni F.
J Clin Pathol. 2022 Sep;75(9):588-592. I.F. 3.411
- 53. A software suite for limb volume analysis applicable in clinical settings: upper limb quantification**
Nascimben M, Lippi L, Fusco N, Invernizzi M, Rimondini L
Front. Bioeng. Biotechnol. 2022 May 30;10:863689. I.F. 5.890
- 54. Pathological examination of breast cancer samples before and after neoadjuvant therapy: Recommendations from the Italian group for the study of breast pathology - Italian Society of Pathology (GIPaM-SIAPeC)**
Fusco N#, Rizzo A, Costarelli L, Santinelli A, Cerbelli B, Scatena C, Macri E, Pietribiasi F, d'Amati G, Sapino A, Castellano I
Pathologica. 2022 Apr;114(2):104-110. I.F.: 3.5
- 55. Vitamin D deficiency in breast cancer women: which correlation with osteoporosis? A machine learning approach with multiple factor analysis**
de Sire A, Gallelli L, Marotta N, Lippi L, Fusco N, Calafiore D, Cione E, Muraca L, Maconi A, De Sarro G, Ammendolia A, Invernizzi M
Nutrients. 2022 Mar, 4(8), 1586 I.F. 6.706
- 56. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: Preclinical and clinical progress**
Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G, Fusco N#
Expert Opin Inv Drugs. 2022 Mar, 31:6, 593-605 I.F. 6.206
- 57. Association between previous negative biopsies and lower rates of disease progression during active surveillance for prostate cancer**
Marvaso G, Ekaterina L, Norimiura J, Schuettfort V, Morikei I, Colombo A, Ferro M, Mistretta FA, Fusco N, Petralia G, Jereczek BA, Shahrokh S, Pik P, De Cobelli O, Musi G, Luzzago S
World J Urol. 2022 Jun;40(6):1447-1454. I.F. 4.226
- 58. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer**
Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, Curigliano G, Criscitiello C, Fusco N#
Front Mol Biosci. 2022 Feb, 9:834651 I.F. 6.133
- 59. Low-risk triple-negative breast cancers: clinico-pathological and molecular features**
Fusco N#, Sajjadi E, Venetis K, Ivanova M, Andaloro S, Guerini-Rocco E, Montagna E, Caldarella P, Veronesi P, Colleoni M, Viale G.
Crit Rev Oncol Hematol. 2022 Feb, 172:103643 I.F. 6.625
- 60. Biomarkers for targeted rehabilitation strategies after breast cancer: proposal for the next-generation management of survivorship issues**
Invernizzi M, Fusco N#
Biocell. 2022 Feb 46(10):2221-2223. I.F. 1.254

- 61. Impact of exercise training on muscle mitochondria modifications in older adults: a systematic review of randomized controlled trials**
Lippi L, de Sire A, Mezian K, Curci C, Perrero L, Turco A, Andaloro S, Ammendolia A, [Fusco N](#), Invernizzi M
Aging Clin Exp Res. 2022 Jan 34, 1495–1510 I.F. **4.481**
- 62. Efficacy of antiresorptive drugs on bone mineral density in post-menopausal women with early breast cancer receiving adjuvant aromatase inhibitors: a systematic review of randomized controlled trials**
de Sire A, Lippi L, Venetis K, Morganti S, Sajjadi E, Curci C, Ammendolia A, Criscitiello C, [Fusco N](#), Invernizzi M
Front. Oncol. 2022 Jan 11:829875 I.F. **6.244**
- 63. A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with low-grade ductal carcinoma in situ of the breast**
Nicosia L, Bozzini AC, Penco S, Trentin C, Pizzamiglio M, Lazzeroni M, Lissidini G, Veronesi P, Farante G, Frassoni S, Bagnardi V, Fodor C, [Fusco N](#), Sajjadi E, Cassano E, Pesapane F
Cancers. 2022 Jan 12;14(2):370. I.F. **6.639**
- 64. Pathology after neoadjuvant treatment – How to assess residual disease**
Viale G, [Fusco N](#)*
Breast. 2022 Mar 62(s1):S25-S28. I.F. **4.380**
- 65. Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis.**
Sajjadi E, Venetis K, [Fusco N](#), Corso G.
Eur J Cancer Prev. 2022 Sep 1;31(5) I.F. **2.497**
- 66. Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies**
Luzzago S, Piccinelli ML, Marvaso G, Laukhtina E, Miura N, Schuettfort VM, Mori K, Aydh A, Ferro M, Mistretta FA, [Fusco N](#), Petralia G, Jereczek-Fossa BA, Shariat SF, Karakiewicz PI, de Cobelli O, Musi G.
World J Urol. 2022 Feb;40(2):443-451. I.F. **4.226**
- 67. Repeat MRIs during Active Surveillance: natural history of prostatic lesions and upgrading rates**
Luzzago S, Luca Piccinelli M, Mistretta FA, Bianchi R, Cozzi G, di Trapani E, Cioffi A, Catellani M, Fontana M, Jannello LMI, Botticelli FMG, Marvaso G, Alessi S, Pricolo P, Ferro M, Matei DV, Jereczek-Fossa BA, [Fusco N](#), Petralia G, de Cobelli O, Musi G.
BJU Int. 2022 Apr;129(4):524-533. I.F. **5.588**
- 68. Quality of life interventions in breast cancer survivors: state of the art in targeted rehabilitation strategies**
Invernizzi M, de Sire A, Venetis K, Cigna E, Carda S, Borg M, Cisari C, [Fusco N](#)*
Anti-Cancer Agents Med. Chem. 2022 Apr 22(4):801-810. I.F. **2.505**
- 69. Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology**
Criscitiello C, Guerini-Rocco E, Viale G, Fumagalli C, Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Malapelle U, [Fusco N](#)#
Anti-Cancer Agents Med. Chem. 2022 Apr 22(4):787-800 I.F. **2.505**
- 70. Physical exercise and whole-body vibration to reduce aromatase inhibitor-induced musculoskeletal symptoms in patients with breast cancer: a pilot randomized controlled trial**
de Sire A, Lippi L, Ammendolia A, Cisari C, Venetis K, Sajjadi E, [Fusco N](#), Invernizzi M
J Pers Med. 2021 Dec 14;11(12):1369 I.F. **4.945**
- 71. Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling**
Sajjadi E, Venetis K, Piciotti R, Gambini D, Blundo C, Runza L, Ferrero S, Guerini-Rocco E, [Fusco N](#)#
BMC Cancer. 2021 Oct 28;21(1):1152 I.F. **4.372**
- 72. Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists**
[Fusco N](#)#, Ragazzi M, Sajjadi E, Venetis K, Piciotti R, Morganti S, Santandrea G, Fanelli GN, Despini L, Invernizzi M, Cerbelli B, Scatena C, Criscitiello C
Histol Histopathol. 2021 Dec;36(12):1235-1245. I.F. **2.303**
- 73. Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients**
Venetis K, [Fusco N](#)#, Sajjadi E
Front Oncol. 2021 Sep 29;11:735476 I.F. **6.244**
- 74. Early breast cancers during pregnancy treated with breast-conserving surgery in the first trimester of gestation: a feasibility study**
Blundo C, Giroda M, [Fusco N](#)#, Sajjadi E, Venetis K, Leonardi MC, Vicini E, Despini D, Rossi CF, Runza L, Sfondrini MS, Piciotti R, Di Loreto E, Scarfone G, Guerini Rocco E, Viale G, Veronesi P, Buonomo B, Peccatori FA, Galimberti VE
Front Oncol. 2021 Aug 24;11:723693 I.F. **6.244**
- 75. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality**

Salati M, Venetis K, Fassan M, Malapelle U, Pagni F, Sajjadi E, [Fusco N[#]](#), Ghidini M
Future Oncol. 2021 Nov;17(33):4607-4618 I.F. **3.404**

76. Molecular Biomarkers in Solid Tumors

[Fusco N[#]](#), Marchio C, Ghidini M, Scatena C
Genes. 2021 Jun 28;12(7):984 I.F. **4.096**

77. Breast cancer with bone metastasis: molecular insights and clinical management

Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, Criscitiello C, [Fusco N[#]](#)
Cells 2021; Jun 10(6):1377 I.F. **6.600**

78. Comparing prognostic utility between the 8th edition of TNM staging system and the lymph node ratio for oral squamous cell carcinoma

Beltramini G, Belloni GA, [Fusco N](#), Sacconi A, Muti P, Baj A, Bolzoni AR, Gianni AB
Head Neck. 2021 Oct;43(10):2876-2882 I.F. **3.147**

79. Mismatch repair-deficient hormone receptor-positive breast cancers: biology and pathological characterization

Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Guerini-Rocco E, Haricharan S, [Fusco N[#]](#)
Cancer Cell Int. 2021 17;21(1):266 I.F. **4.175**

80. An EBC/plasma miRNA signature discriminates lung adenocarcinomas from pleural mesothelioma and healthy controls

Faversani A, Favero C, Dioni L, Pesatori AC, Bollati V, Montoli M, Musso V, Terrasi A, [Fusco N](#), Nosotti M, Vaira V, Palleschi A
Front Oncol 2021;11:643280 I.F. **6.244**

81. How to best exploit immunotherapeutics in advanced gastric cancer: between biomarkers and novel cell-based approaches

Ghidini M, Petrillo A, Botticelli A, Trapani D, Parisi A, La Salvia A, Sajjadi E, Piciotti R, [Fusco N](#), Khakoo S
J Clin Med. 2021 Apr 10, 1412 I.F. **3.303**

82. Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients

Invernizzi M, Venetis K, Sajjadi E, Piciotti R, de Sire A, [Fusco N[#]](#)
Curr. Opin. Pharmacol. 2021 Jun 57:132–139 I.F. **5.547**

83. Lymphedema rehabilitation using self-adaptive inelastic compression in breast cancer: a proof-of-principle study

de Sire A, [Fusco N](#), Sajjadi E, Lippi L, Cisari C, Invernizzi M
Appl Sci. 2021 11(4),1901:1-8 I.F. **2.474**

84. The role of the pathologist in the next-generation era of tumor molecular characterization

Angerilli V, Galuppini F, Pagni F, [Fusco N](#), Malapelle U, Fassan M
Diagnostics. 2021 Feb 18;11(2):339 I.F. **3.110**

85. Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: synergy between nutritional supplementation, pharmacotherapy, and rehabilitation

Invernizzi M, de Sire A, [Fusco N^{*}](#)
Curr. Opin. Pharmacol. 2021 Apr 57:132-139 I.F. **5.547**

86. PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer

[Fusco N^{*}](#), Malapelle U, Fassan M, Marchiò C, Buglioni S, Zupo S, Criscitiello C, Vigneri P, Dei Tos AP, Maiorano E, Viale G
Front Oncol. 2021 Mar 25;11:644737 I.F. **4.848**

87. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy

Ghidini M, [Fusco N](#), Salati M, Khakoo S, Tomasello G, Petrelli F, Trapani D
Current Drug Targets. 2021 22(9):1021-1033 I.F. **2.632**

88. PD-L1 testing and squamous cell carcinoma of the head and neck: a multicenter study on the diagnostic reproducibility of different protocols

Crosta S, Boldorini R, Bono F, Brambilla V, Dainese E, [Fusco N^{*}](#), Gianatti A, L'Imperio V, Morbini P, Pagni F
Cancers (Basel). 2021 Jan 14;13(2):292 I.F. **6.126**

89. Digital slides as an effective tool for PD-L1 Combined Positive Score (CPS) assessment and training: Lessons learned from the "PD-L1 Key Learning Program in Head and Neck Squamous Cell Carcinoma"

Eccher A, Fontanini G, [Fusco N](#), Girolami I, Graziano P, Guerini-Rocco E, Martini M, Morbini P, Pantanowitz L, Parwani A, Pisano AM, Troncone G, Vigliar E.
J Pathol Inform. 2021 Jan 8;12:1 I.F. **2.880**

90. Body mass index, adiposity and tumor infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: a multi-parametric analysis

Esposito A, Marra A, Bagnardi V, Frassoni S, Morganti S, Viale G, Zagami P, Varano GM, Buccimazza G, Orsi F, Venetis K,

Mazzarella L, Viale G, Fusco N, Criscitiello C, Curigliano G.
Eur J Cancer. 2021 Mar;145:197-209 I.F. **7.275**

91. **The Genetic Landscape of Metaplastic Breast Cancers and Uterine Carcinosarcomas**
 Moukarzel L, Ferrando L, Da Cruz Paula A, Brown DN, Geyer FC, Pareja F, Piscuoglio S, Papanastasiou AD, Fusco N, Marchiò C, Abu-Rustum NR, Murali R, Brogi E, Wen HY, Norton L, Soslow RA, Vincent-Salomon A, Reis-Filho JS, Weigelt B.
Mol Oncol. 2020 Apr;15(4):1024-1039 I.F. **6.574**
92. **Biomarkers for precision immunotherapy: hope or reality?**
 Sajjadi E, Venetis K, Scatena C, Fusco N[#]
eCancerMedicalScience. 2020 Dec 3;14:1150 I.F. **1.8**
93. **Editorial: Quality of Life in Breast Cancer Patients and Survivors**
 Invernizzi M, Kim J, Fusco N[#]
Front Oncol. 2020 Nov 18;10:620574 I.F. **4.848**
94. **Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients**
Fusco N[#], Vaira V, Righi I, Sajjadi E, Venetis K, Lopez G, Cattaneo M, Castellani M, Rosso L, Nosotti M, Clerici M, Ferrero S
Lung Cancer. 2020 Oct, 2;150:53-61 I.F. **4.702**
95. **Impact of rehabilitation on breast cancer related fatigue: a pilot study**
 Invernizzi M, De Sire A, Lippi L, Venetis K, Sajjadi E, Gimigliano F, Gennari A, Criscitiello C, Cisari C, Fusco N^{*}
Front Oncol. 2020 Sep Oct 21;10:556718 I.F. **4.848**
96. **Mismatch repair system genomic scars in gastroesophageal cancers: biology and clinical testing**
 Lopez G, Venetis K, Sajjadi E, Fusco N[#].
Gastrointest Disord. 2020 Sep. 2(4), 341-352 I.F. **0.7**
97. **Cellular immunotherapy in breast cancer: the quest for consistent biomarkers**
 Venetis K, Invernizzi M, Sajjadi E, Curigliano G, Fusco N[#]
Cancer Treat Rev. 2020 Nov;90:102089 I.F. **8.885**
98. **Digital pathology and PD-L1 testing in non-small cell lung cancer: a workshop record**
 Pagni F, Malapelle U, Doglioni C, Gabriella F, Fraggetta F, Graziano P, Marchetti A, Guerini Rocco E, Pisapia P, Vigliar EV, Buttitta F, Jaconi M, Fusco N, Barberis M, Troncone G.
Cancers (Basel). 2020 Jul 5;12(7):1800. I.F. **6.126**
99. **PTEN alterations and their role in cancer management: are we making headway on precision medicine?**
Fusco N[#], Sajjadi E, Venetis K, Gaudioso G, Lopez G, Corti C, Guerini-Rocco E, Criscitiello C, Malapelle U, Invernizzi M.
Genes. 2020 Jun, 11, 719. I.F. **3.759**
100. **Hereditary gastric and breast cancer syndromes related with CDH1 germline mutation: a multidisciplinary clinical review**
 Corso G, Montagna G, Figueiredo J, La Vecchia C, Fumagalli Romario U, Fernandes MS, Seixas S, Roviello F, Trovato C, Guerini-Rocco E, Fusco N, Pravettoni G, Petrocchi S, Rotili A, Massari G, Magnoni F, De Lorenzi F, Bottoni M, Galimberti V, Sanchez JM, Calvello M, Seruca R, Bonanni B
Cancers. 2020 Jun 17;12(6):E1598. I.F. **6.162**
101. **Pharmacological management of male breast cancer.**
 Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzarella L, Criscitiello C, Esposito A, Curigliano G.
Expert Opinion on Pharmacotherapy. 2020 Jun 21:12, 1493-1504 I.F. **3.038**
102. **Axillary web syndrome in women after breast cancer surgery referred to an Oncological Rehabilitation Unit: which are the main risk factors? A retrospective case-control study.**
 de Sire A, Losco L, Cisari C, Gennari A, Boldorini R, Fusco N, Cigna E, Invernizzi M
Eur Rev Med Pharmacol Sci. 2020 24: 8028-8035 I.F. **3.024**
103. **Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers.**
 Venetis K, Sajjadi E, Haricharan S, Fusco N[#]
Transl Cancer Res. 2020 May 21:12, 1493-1504 I.F. **1.070**
104. **Spinal cord injury as a model of bone-muscle interactions: therapeutic implications from in vitro and in vivo studies.**
 Invernizzi M, de Sire A, Renò F, Cisari C, Runza L, Baricich A, Carda S, Fusco N
Front Endocrinol. 2020 Apr 11:204 I.F. **3.634**
105. **Bone-muscle crosstalk in spinal cord injuries: pathophysiology and implications for patients' quality of life.**
 Invernizzi M, de Sire A, Carda S, Venetis K, Renò F, Cisari C, Fusco N^{*}
Curr Osteoporos Rep. 2020 June 18:422-431 I.F. **3.927**

- 106. Three-dimensional laser scanning as a reliable and reproducible diagnostic tool in breast cancer related lymphedema rehabilitation: a proof-of-principle study.**
De Sire A, Cigna E, Losco L, Lippi L, Gimigliano F, Gennari A, Cisari C, Chen HC, [Fusco N](#), Invernizzi M
Eur Rev Med Pharmacol Sci. 2020; 24(8):4476-4485 I.F. **2.721**
- 107. Integrating biological advances into the clinical management of breast cancer related lymphedema.**
Invernizzi M, Lopez G, Michelotti A, Venetis K, Sajjadi E, De Mattos-Arruda L, Ghidini M, Runza L, De Sire A, Boldorini R, [Fusco N](#)[#]
Front Oncol. 2020; 10:422 I.F. **4.137**
- 108. PTEN expression as a complementary biomarker for mismatch repair testing in breast cancer.**
Lopez G, Noale M, Corti C, Gaudio G, Sajjadi E, Venetis K, Gambini D, Runza L, Costanza J, Pesenti C, Grossi F, Maggi S, Ferrero S, Bosari S, [Fusco N](#)[#]
Int J Mol Sci. 2020; 21(4):1461 I.F. **4.183**
- 109. Integrating augmented reality tools in breast cancer related lymphedema prognostication and diagnosis.**
Invernizzi M, Runza L, De Sire A, Lippi L, Blundo C, Gambini D, Boldorini R, Ferrero S, [Fusco N](#)[#]
J Vis Exp. 2020; (156):10.3791/60093 IF: **1.325**
- 110. Strategies for increasing the effectiveness of aromatase inhibitors in locally advanced breast cancer: an evidence-based review on current options.**
Grizzi G, Ghidini M, Botticelli A, Tomasello G, Ghidini A, Grossi F, [Fusco N](#), Cabiddu M, Savio T, Petrelli F
Cancer Manag Res. 2020; 12:675-686. I.F. **2.243**
- 111. RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.**
Lopez G, [Fusco N](#)[#]
Breast Cancer Res Treat. 2020; 180(1):265-266 I.F. **3.471**
- 112. Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study.**
De Sire A, Baricich A, Renò F, Cisari C [Fusco N](#), Invernizzi M
Aging Clin Exp Res. 2020; 32(5):959-962 I.F. **2.331**
- 113. Targeting immune-related biological processes in solid tumors: we do need biomarkers.**
Pagni F, Guerini-Rocco E, Schultheis A, Grazia G, Rijavec E, Ghidini M, Lopez G, Venetis K, Croci GA, Malapelle U, [Fusco N](#)[#]
Int J Mol Sci. 2019;1;20(21). pii: E5452. I.F. **4.183**
- 114. Columnar cell lesion and apocrine hyperplasia of the breast: is there a common origin? The role of prolactin-induced protein.**
Sciarra A, Lopez G, Corti C, Runza L, Ercoli G, Bonometti A, Despini L, Blundo C, Gambini D, [Fusco N](#)[#].
Appl Immunohistochem. 2019; 27:508-514. IF: **2.042**
- 115. A novel integrated platform for the identification of surgical margins in oral squamous cell carcinoma: results from a prospective single-Institution series.**
Baj A, [Fusco N](#)^{*}, Bolzoni A, Carioli D, Mazzucato C, Faversani A, Bresciani L, Maggioni M, Capaccio P
BMC Cancer. 2019;19(1):467. IF: **3.288**
- 116. The conundrum of breast chondrolipoma: heterotopic, metaplastic, or neoplastic lesion?**
Sabella G, Lopez G, Runza L, Rognoni E, Sfondrini MS, [Fusco N](#)[#]
Breast J. 2019;25(4):733–734. IF: **2.424**
- 117. Chondroid differentiation in thyroid nodular hyperplasia: an innocent bystander?**
Pittaro A, Del Gobbo A, Iofrida E, [Fusco N](#)[#]
Int J Surg Pathol. 2019;27(3):274. IF: **1.188**
- 118. TdT expression in germ cell tumors: a possible immunohistochemical cross-reaction and diagnostic pitfall.**
Jaconi M, Magni F, Raimondo F, Ponzoni M, Chinello C, Smith A, Piga I, [Fusco N](#), Di Bella C, Pagni F.
J Clin Pathol. 2019;72(8):536–541 I.F. **2.894**
- 119. The reproducibility of the immunohistochemical PD-L1 testing in Non Small Cell Lung Cancer: a multicentric Italian experience**
Vigliar E, Malapelle U, Bono F, [Fusco N](#), Cortinovis DL, Valtorta E, Spyridon A, Bimbatti M, Zocchi M, Piva C, Gaudio G, Iaccarino A, Morbini P, Pagni F
Biomed Res Int 2019 Apr 14;2019:6832909. I.F. **2.583**
- 120. Diagnostic challenge of intrathoracic tissue misplacements: a thymic choristoma in a fetal lung.**
Lopez G, Croci R, Rizzuti T, Ferrero S, [Fusco N](#)[#]
Thorax 2019;74(6):624. I.F. **9.655**

- 121. Tackling the diversity of breast cancer related lymphedema: perspectives on diagnosis, risk assessment, and clinical management.**
Michelotti A, Invernizzi M, Lopez G, Lorenzini D, Nesa F, De Sire A, [Fusco N[#]](#)
Breast 2019;44:15-23. **I.F. 2.951**
- 122. NF1 alterations are linked to increased HER2 expression in breast cancer - Letter.**
Gambini D, Natacci F, Cesaretti C, [Fusco N[#]](#)
Cancer Prev Res. 2019 Mar 12(3). **I.F. 4.021**
- 123. Determination of mismatch repair status in human cancer and its clinical significance: does one size fit all?**
Corti C, Sajjadi E, [Fusco N[#]](#)
Adv Anat Pathol 2019 Jul;26(4) **I.F. 6.7**
- 124. Impact of mutation density and heterogeneity of papillary thyroid cancer clinical features and remission probability.**
Colombo C, Muzza M, Proverbio MC, Tosi D, Soranna D, Pesenti C, Rossi S, Cirello V, De Leo S, [Fusco N](#), Miozzo M, Bulfamante G, Vicentini L, Ferrero S, Zambon A, Tabano S, Fugazzola L.
Thyroid. 2019 Feb 29(2) **I.F. 7.557**
- 125. Molecular insights into the classification of Luminal breast cancers: the genomic heterogeneity of progesterone-negative tumors.**
Lopez G, Costanza J, Colleoni M, Fontana L, Ferrero S, Miozzo M, [Fusco N[#]](#)
Int J Mol Sci. 2019 Jan 25;20(3) **I.F. 3.687**
- 126. Breast cancer systemic treatments and upper limb lymphedema: a risk-assessment platform encompassing tumor-specific pathological features reveals the potential role of trastuzumab.**
Invernizzi M, Michelotti A, Noale M, Lopez G, Runza L, Giroda M, Despini L, Blundo C, Maggi S, Gambini D, [Fusco N[#]](#)
J Clin Med 2019 Jan 8(2):138. **I.F. 5.583**
- 127. The genetic landscape of human glioblastoma and matched primary cancer stem cells reveals intra-tumour similarity and inter-tumour heterogeneity.**
Pesenti C, Navone SE, Guarnaccia L, Terrasi A, Costanza J, Silipigni R, Guarneri S, [Fusco N](#), Fontana L, Locatelli M, Rampini P, Campanella R, Tabano S, Miozzo M, Marfia G.
Stem Cells Int 2019 Mar 7;2019:2617030 **I.F. 3.989**
- 128. Molecular and immunohistochemical markers with prognostic and predictive significance in liver metastases from colorectal carcinoma.**
Lopez G, Boggio F, Ferrero S, [Fusco N[#]](#), Del Gobbo A.
Int J Mol Sci. 2018 Oct 3;19(10) **I.F. 3.687**
- 129. Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer-related lymphedema: an observational retrospective study with long-term follow-up.**
Invernizzi M, Corti C, Lopez G, Michelotti A, Despini L, Gambini D, Lorenzini D, Guerini-Rocco E, Maggi S, Noale M, [Fusco N[#]](#)
BMC Cancer. 2018 Sep 18(1):935. **IF: 3.288**
- 130. CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours. A multicentric study with emphasis on atypical carcinoids.**
Del Gobbo A, [Fusco N](#), Barella M, Ercoli G, Sciarra A, Palleschi A, Pagni F, Marchio C, Papotti M, Ferrero S.
Cell Oncol (Dordr). 2018 2018 Dec;41(6):687-691. **IF: 4.761**
- 131. Mismatch repair protein loss is a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability**
[Fusco N[#]](#), Lopez G, Corti C, Pesenti C, Colapietro P, Ercoli G, Gaudio G, Favarsani A, Gambini D, Michelotti A, Despini L, Blundo C, Vaira V, Miozzo M, Ferrero S, Bosari S.
JNCI Cancer Spectrum. 2018 Nov;2(4):pky056. **I.F. 4.4**
- 132. Pathologic grading of malignant pleural mesothelioma: An evidence-based proposal.**
Pelosi G, Papotti M, Righi L, Rossi G, Ferrero S, Bosari S, Calabrese F, Kern I, Maisonneuve P, Sonzogni A, Albini A, Harari S, Barbieri F, Capelletto E, Catino AM, Cavone D, De Palma A, [Fusco N](#), Lunardi F, Maiorano E, Marzullo A, Novello S, Papanikolaou N, Pasello G, Pennella A, Pezzuto F, Punzi A, Prisciandaro E, Rea F, Rosso L, Scattone A, Serio G.
J Thoracic Oncol. 2018 Nov;13(11):1750-1761. **IF: 10.331**
- 133. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.**
De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim R, De Filippo M, [Fusco N](#), Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Cajal SR, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS.
Oncotarget. 2018 Apr;9(29): 20617-20630. **IF: 5.168**
- 134. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.**
Smith A, Galli M, Piga I, Denti V, Stella M, Chinello C, [Fusco N](#), Leni D, Manzoni M, Roversi G, Garancini M, Pincelli AI, Cimino V,

Capitoli G, Magni F, Pagni F.

J Proteomics. 2018 Mar S1874-3919(18)30122-2. **IF: 3.867**

135. Rathke's cleft cyst associated with pituitary granulomatosis with polyangiitis: An unusual combination of hypothalamus-pituitary region pathologies

Draghi R, Mantovani G, Runza L, Carrabba G, Fusco N, Rampini P, Costa A, Locatelli M

Radiol Case Rep. 2018 Feb 13(1): 233–236 **I.F. 1**

136. MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.

Kim J, Geyer FC, Martelotto LG, Ng CKY, Lim RS, Selenica P, Li A, Pareja F, Fusco N, Edelweiss M, Kumar R, Gularte-Merida R, Forbes AN, Khurana E, Mariani O, Badve S, Vincent-Salomon A, Norton L, Reis-Filho JS, Weigelt B.

J Pathol. 2018 Feb;244(2):143-150. **IF: 6.894**

137. Building up a high-throughput screening platform to assess the heterogeneity of HER2 gene amplification in breast cancers.

Ercoli G, Lopez G, Ciapponi C, Corti C, Despini L, Gambini D, Runza L, Blundo C, Sciarra A, Fusco N^.

J Vis Exp. 2017 Dec 5;(130). **IF: 1.325**

138. Looking for sputum biomarkers in lung cancer secondary prevention: where are we now?

Fusco N^, Fumagalli C, Guerini-Rocco E.

J Thorac Dis. 2017 Nov;9(11):4277-4279. **IF: 2.365**

139. Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells.

Peverelli E, Catalano R, Giardino E, Treppiedi D, Morelli C, Ronchi CL, Vaczlavik A, Fusco N, Ferrero S, Bertherat J, Beuschlein F, Chiodini I, Arosio M, Spada A, Mantovani G.

Cancer Letters. 2017 Oct 10;406:54-63. **IF: 6.375**

140. Recurrent NAB2-STAT6 gene fusions and estrogen receptor alpha expression in pulmonary adenofibromas.

Fusco N^, Guerini-Rocco E, Augello C, Terrasi A, Ercoli G, Fumagalli C, Vacirca D, Braidotti P, Parafioriti A, Jaconi M, Runza L, Ananthanarayanan V, Pagni F, Bosari S, Barberis M, Ferrero S

Histopathology. 2017 May;70(6):1000-1008. **IF: 6.4**

141. Clonal reticulohistiocytosis of the skin and bone marrow associated with systemic mastocytosis and acute myeloid leukaemia.

Fusco N^, Bonometti A, Augello C, Fabris S, Boiocchi L, Fiori S, Morotti D, Fracchiolla N, Berti E, Gianelli U

Histopathology. 2017 May;70(6):906-917. **IF: 6.4**

142. Circulating and tissue biomarkers in early-stage non-small cell lung cancer.

Fumagalli C, Bianchi F, Rafaniello P, Vacirca D, Bertalot G, Rampinelli C, Lazzeroni M, Bonanni B, Veronesi G, Fusco N, Barberis M, Guerini-Rocco E

Ecancermedalscience. 2017 Jan 31;11:717. **IF: 1.120**

143. Hibernation in unusual places: a pure typical hibernoma of the breast.

Runza L, Blundo C, Guerini-Rocco E, Forno I, Fusco N^.

Breast J. 2017 Jan;23(1):104-105. **IF: 2.424**

144. Autoimmune hepatitis: an uncommon presentation of thymoma.

Mendogni P, Rosso L, Tosi D, Palleschi A, Righi I, Minonzio F, Fusco N, Nosotti M.

Tumori. 2016 Nov 11;102(Suppl. 2). **IF: 1.071**

145. Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Fusco N^, Geyer FC, De Filippo MR, Martelotto LG, Ng CK, Piscuoglio S, Guerini-Rocco E, Schultheis AM, Fuhrmann L, Wang L, Jungbluth AA, Burke KA, Lim RS, Vincent-Salomon A, Bamba M, Moritani S, Badve SS, Ichihara S, Ellis IO, Reis-Filho JS, Weigelt B.

Mod Pathol. 2016 Nov;29(11):1292-1305. **IF: 5.485**

146. Therapeutic potential of immunoproteasome inhibition in Duchenne muscular dystrophy.

Farini A, Sitzia C, Cassani B, Cassinelli L, Rigoni R, Colleoni F, Fusco N, Gatti S, Bella P, Villa C, Napolitano F, Maiavacca R, Bosari S, Villa A, Torrente Y.

Mol Ther. 2016 Nov;24(11):1898-1912. **IF: 6.938**

147. HER2 aberrations and heterogeneity in cancers of the digestive system: implications for pathologists and gastroenterologists.

Fusco N^, Bosari S.

World J Gastroenterol. 2016 Sep 21;22(35):7926-37. **IF: 2.787**

148. The genomic landscape of male breast cancer.

Piscuoglio S, Ng CKY, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, Bidard FC, Berman S, Fusco N, Sakr RA, Eberle C, De Mattos-Arruda L, Macedo GS, Akram M, Baslan T, Hicks J, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS. **Clin Cancer Res.** 2016 Aug 15;22(16):4045-56. **IF: 8.738**

149. Lack of PRKD2 and PRKD3 kinase domain somatic mutations in PRKD1 wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland.

Piscuoglio S, Fusco N, Ng CK, Martelotto LG, da Cruz Paula A, Katabi N, Rubin BP, Skálová A, Weinreb I, Weigelt B, Reis-Filho JS. **Histopathology.** 2016 Jun;68(7):1055-62. **IF: 6.4**

150. Rediscovering secondary tumors of the prostate in the molecular era.

Fusco N*, Sciarra A, Guerini-Rocco E, Marchiò C, Vignani F, Colombo P, Ferrero S. **Adv Anat Pathol.** 2016 May;23(3):170-9. **IF: 2.919**

151. Approaching the histodynamics of celiac disease in modern times: the need of going beyond the dogmas.

Fusco N*, Runza L, Elli L, Ferrero S. **Dig Liver Dis.** 2016 Apr;48(4):449-50. **IF: 5.165**

152. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.

Guerini-Rocco E, Piscuoglio S, Ng CK, Geyer FC, De Filippo MR, Eberle CA, Akram M, Fusco N, Ichihara S, Sakr RA, Yatabe Y, Vincent-Salomon A, Rakha EA, Ellis IO, Wen YH, Weigelt B, Schnitt SJ, Reis-Filho JS. **J Pathol.** 2016 Apr;238(5):677-88. **IF: 6.894**

153. Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing.

Fusco N*, Colombo PE, Martelotto LG, De Filippo MR, Piscuoglio S, Ng CK, Lim RS, Jacot W, Vincent-Salomon A, Reis-Filho JS, Weigelt B. **Histopathology.** 2016 Jan;68(2):262-271. **IF: 6.4**

154. "Giants in a microcosm": multinucleated giant cells populating an invasive micropapillary carcinoma of the breast.

Marchiò C, Pietribiasi F, Castiglione R, Fusco N, Sapino A. **Int J Surg Pathol.** 2015 Dec;23(8):654-5 **IF: 1.188**

155. The contrasting role of p16Ink4A patterns of expression in neuroendocrine and non-neuroendocrine lung tumors: a comprehensive analysis with clinicopathologic and molecular correlations.

Fusco N*, Guerini-Rocco E, Del Gobbo A, Franco R, Zito-Marino F, Vaira V, Bulfamante G, Ercoli G, Nosotti M, Palleschi A, Bosari S, Ferrero S. **PLoS One.** 2015 Dec 16;10(12):e0144923. **IF: 3.057**

156. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.

Piscuoglio S, Murray M, Fusco N, Marchiò C, Loo FL, Martelotto LG, Schultheis AM, Akram M, Weigelt B, Brogi E, Reis-Filho JS. **Histopathology.** 2015 Nov;67(5):719-29. **IF: 6.4**

157. Role of multidisciplinary approach in a case of Langerhans cell histiocytosis with initial periodontal manifestations.

Cisternino A, Asa'ad F, Fusco N, Ferrero S, Rasperini G. **Int J Clin Exp Pathol.** 2015 Oct 1;8(10):13539-45. **IF: 1.581**

158. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.

Guerini-Rocco E, Hodi Z, Piscuoglio S, Ng CK, Rakha EA, Schultheis AM, Marchiò C, da Cruz Paula A, De Filippo MR, Martelotto LG, De Mattos-Arruda L, Edelweiss M, Jungbluth AA, Fusco N, Norton L, Weigelt B, Ellis IO, Reis-Filho JS. **J Pathol.** 2015 Oct;237(2):166-78 **IF: 6.894**

159. Basal cell carcinoma and seborrheic keratosis: when opposites attract.

Fusco N#, Lopez G, Gianelli U. **Int J Surg Pathol.** 2015 Sep;23(6):464. **IF: 1.188**

160. The birth of an adenoid cystic carcinoma.

Fusco N*, Guerini-Rocco E, Schultheis AM, Badve SS, Reis-Filho JS, Weigelt B. **Int J Surg Pathol.** 2015 Feb;23(1):26-7. **IF: 1.188**

161. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.

Weinreb I, Piscuoglio S, Martelotto L, Waggott D, Ng C, Perez-Ordóñez B, Alfaro J, Kislinger T, Viale A, Fusco N, Da Cruz Paula A, Lim R, Thompson L, Chiosea SI, Seethala RS, Skalova A, Stelow EB, Fonseca I, Assaad A, How C, Liu FF, Wen YH, Katabi N, Buchner N, Mullen L, McPherson JD, Norton L, Rubin BP, Weigelt B, Clarke BA, Boutros P, Reis-Filho JS. **Nat Genet.** 2014 Nov;46(11):1166-9. **IF: 31.616**

- 162. Acitretin-induced acral hemorrhagic lesions in Darier-White disease.**
Zavattaro E, Celasco M, Delrosso G, Ferri S, Bornacina C, Valente G, Veronese F, [Fusco N](#), Gariglio M, Colombo E.
Cutis. 2014 Dec;94(6):E1-5. **IF: 1.6**
- 163. Expression and clinical significance of the autophagy proteins BECLIN 1 and LC3 in ovarian cancer.**
Valente G, Morani F, Nicotra G, [Fusco N](#), Peracchio C, Alabiso O, Arisio R, Katsaros D, Benedetto C, Isidoro C.
Biomed Res Int. 2014;462658. **IF: 3.246**
- 164. Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.**
Cucchiari D, Bertuzzi A, Colombo P, De Sanctis R, Faucher E, [Fusco N](#), Pellegrinelli A, Arosio P, Angelini C.
J Clin Oncol. 2013 May 10;31(14):e240-2. **IF: 45.3**
- 165. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.**
[Fusco N](#)*, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, Romagnoli S, Bosari S.
Mod Pathol. 2013 Jun;26(6):816-24. **IF: 7.5**
- 166. High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome.**
Nicotra G, Manfroi F, Follo C, Castino R, [Fusco N](#), Peracchio C, Kerim S, Valente G, Isidoro C.
Dis Markers. 2010;28(3):167-83. **IF: 3.464**

Publications (no IF and/or educational)

- Liquid Biopsy: Cell-free DNA based analysis in Breast Cancer**
Venetis K, Cursano G, Pescia C, D'Ercole M, Porta FM, Cruz Blanco M, Frascarelli C, Guerini-Rocco E, [Fusco N](#)[#]
J Liquid Biopsy 2023 Jul [ahead of print]
- Hereditary gastric and breast cancer syndromes with lung metastasis: narrative review of molecular and clinical insights**
Ivanova M, Evangelista J, Venetis K, Sajjadi E, Lococo F, Corso G, Ghidini M, [Fusco N](#)[#]
AME Surgical Journal. 2023 3;39
- Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls**
Morganti S, Ivanova M, Ferraro E, Ascione L, Vivinet G, Bonizzi G, Curigliano G, [Fusco N](#), Criscitiello C
Cancer Drug Resist 2022 (5)971-80
- Improving HER2 testing reproducibility in HER2-low breast cancer.**
Sajjadi E, Venetis K, Ivanova M, [Fusco N](#)[#]
Cancer Drug Resist. 2022 June
- Mismatch repair status characterization in oncologic pathology: taking stock of the real-world possibilities**
Piciotti R, Venetis K, Sajjadi E, [Fusco N](#)[#]
J Mol Path. 2021 Apr
- From Traditional Histology to Next-Generation Pathology: A Review of The Workflow for the Characterisation and Molecular Profiling of Non-Small Cell Lung Cancer Samples**
Malapelle U, Fusco N*, Pisapia P, Pagni F
EMJ Oncol. 2020 Feb

Book chapters

- **Pathology and Somatic Alterations in Hereditary Lobular Breast Cancers**
Porta FM, Cruz Blanco M, Ivanova M, [Fusco N](#), Guerini Rocco E.
Hereditary Gastric and Breast Cancer Syndrome. Springer 2023
- **HER2 Testing in Breast and Gastric Cancer with CDH1 Germline Mutations**
Ivanova M, Sajjadi E, Zattoni L, [Fusco N](#) (Editors: Corso G, Veronesi P, Roviello F)
Hereditary Gastric and Breast Cancer Syndrome. Springer 2023
- **Mismatch repair status characterization as an immune-related biomarker in oncology**
[Fusco N](#), Venetis K (Editor: Rezaei N)
Handbook of Cancer and Immunology. Springer 2023
- **Tubular adenoma of the breast.**
[Fusco N](#), Corti C. (Editors: Sapino A, Kulka J)
Breast Pathology, Encyclopedia of Pathology 379-384. Springer, 2020
- **Premalignant and preinvasive lesions of the breast.**
[Fusco N](#), Guerini-Rocco E. (Editors: Veronesi U, Goldhirsch A, Veronesi P, Gentilini OD, Leonardi MC)
Breast Cancer: Innovations in Research and Management. 103-120. Springer, 2017

Conference papers and presentations and invited talks in several international congresses